$MOLN News

Molecular Partners Q1 EPS $(0.45) Misses $(0.38) Estimate

Molecular Partners Announces Publication Of Phase 1 Clinical Data In 'Nature Cancer' That Illustrate The Potential Of Tumor-Localized CD40 Agonist, MP0317, To Modulate The Tumor Microenvironment

HC Wainwright & Co. Reiterates Buy on Molecular Partners, Maintains $13 Price Target

Reported Sunday, Molecular Partners Nominates MP0632 As First Logic-Gated Switch-DARPin T Cell Engager Candidate For MSLN/EpCAM-Expressing Solid Tumors With Favorable Therapeutic Window At AACR 2026

Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712

Molecular Partners Announces all Board Proposals Approved, Clare Fisher Elected as New Board Member at Annual General Meeting

Molecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of Directors

Molecular Partners Presents New Preclinical Data Highlighting Radio-DARPins’ Amenability to Multiple Isotopes

Molecular Partners Highlights Radio-DARPin Platform's Interchangeability Of Alpha-Isotopes Including 212Pb And 225Ac In New Preclinical Data

Molecular Partners to Hold Three Poster Presentations at AACR 2026

HC Wainwright & Co. Reiterates Buy on Molecular Partners, Maintains $13 Price Target

Molecular Partners Reports Highlights and Financial Results for Full Year 2025

Molecular Partners Q4 EPS $(0.41) Misses $(0.38) Estimate.

Molecular Partners Signs Development Agreement with Eckert & Ziegler for Targeted Alpha Radiotherapeutics

Molecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial Results

Molecular Partners Enters Development Agreement With Eckert & Ziegler, Leveraging Berlin Alpha Laboratory For Radio-DARPin Radiopharmaceutical Advancement

Molecular Partners Enters Development Agreement With Eckert & Ziegler, Leveraging Berlin Alpha Laboratory For Radio-DARPin Radiopharmaceutical Advancement

Molecular Partners AG (MOLN) Discusses Clinical Imaging and Dosimetry Data for DLL3 Targeting Radiotherapeutic MPO712 - Slideshow

Molecular Partners Highlights Favorable MP0712 DLL3 Radiotherapeutic Imaging, U.S. Phase I/II Ready

Molecular Partners AG (MOLN) Discusses Clinical Imaging and Dosimetry Data for DLL3 Targeting Radiotherapeutic MPO712 Transcript